ClinicalTrials.gg
RecruitingNCT06888726Updated Jun 4, 2025

Efficacy of Hi-tACS for Schizophrenia Negative Symptoms

An interventional study of High-intensity transcranial alternating current stimulation (Hi-tACS) and Sham High-intensity transcranial alternating current stimulation (Sham-Hi-tACS) in Schizophrenia; Negative Type and Transcranial Alternating Current Stimulation, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Jun 2024, registered Feb 2025).
  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Schizophrenia by Shanghai Mental Health Center — 15 open to participants now, 15 under way, none of them phase 3. Schizophrenia · Shanghai Mental Health Center.

Planned enrollment
28th of 50
60 · median 67
Started
2024
with 2 others
No phase
35 of 61
10 open now
Primary completion
2025-11
later than 1 of 14 live
Registered
52nd of 61
by date

Among the 61 studies in Schizophrenia by Shanghai Mental Health Center, this one is the 28th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2024, is one of 35 with no phase, reaches primary completion later than 1 of the 14 other live ones, and was the 52nd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

15 of the 61 studies in Schizophrenia by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Schizophrenia by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate whether Hi-tACS is effective and safe in treating negative symptoms of schizophrenia.

Schizophrenic patients will receive treatment (Hi-tACS or shame stimulation) for 2 weeks.

Negative symptoms, cognitive functioning, social functioning, and quality of life of intervention group and control group were assessed and compared between the two groups at baseline, 2 weeks, and 3 months post-intervention.

Read the detailed description

Objective: To investigate the therapeutic effects and short-term and long-term efficacy of high-intensity transcranial alternating current stimulation (Hi-tACS) on negative symptoms of schizophrenia.

Methods: A randomized controlled design was used, 60 schizophrenic patients who met the enrollment criteria were randomly assigned to either the Hi-tACS intervention group or the sham stimulation control group. Both groups continued their regular medication regimen. The intervention group received continuous current stimulation, while the control group received only 40 seconds of current stimulation per session. The treatment was administered twice daily (morning and afternoon) from Monday to Friday for 2 weeks, with each session lasting 40 minutes, for a total of 20 sessions. Negative symptoms, cognitive function, social function, and quality of life were assessed at baseline, 2 weeks, and 3 months post-intervention.

The primary outcome will be clinical symptoms, the secondary outcome will be the social function and quality of life, and the process measures included social cognition and neurocognition.

03

Conditions studied

  • Schizophrenia; Negative Type
  • Transcranial Alternating Current Stimulation

Browse trials for

Keywords

  • Hi-tACS
  • Schizophrenia
  • Randomized Controlled Trial
  • Negative symptoms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Han Chinese population;
  • Age ≥ 18 years;
  • Education level ≥ 6 years, able to fill out questionnaires on their own, and having sufficient audiovisual level to complete the necessary examinations;
  • Meets diagnostic criteria for schizophrenia as assessed by MINI 7.0;
  • Residual negative symptoms, with at least one item ≥2 on the negative subscale of PANSS (N1-N7);
  • Taking second-generation atypical antipsychotic medication, with no medication or dosage adjustments in the last two weeks
  • Patients and guardians agreed to participate in the study and signed an form.

Exclusion criteria

Exclusion Criteria:

  • Meets diagnostic criteria for other mental disorders;
  • Total score ≥19 on the PANSS positive subscales (P1-P7) ;
  • Severe negative symptoms that prevent the patient from completing the required assessments and interventions;
  • Serious physical or central nervous system disease (intracranial infection, intracranial tumor, presence of metal objects in the skull; epilepsy, seizures; history of hydrocephalus or central nervous system tumors; with implanted electronic devices; serious cardiac disease and fitted with a pacemaker, etc.);
  • Impaired skin integrity at the site of electrode placement or to electrode gels or adhesives;
  • Mental retardation (Wechsler Adult Intelligence Scale WAIS \<70) and/or severe cognitive impairment (Brief Mental State Examination \<24);
  • Presence of vision and/or hearing problems that prevent completion of relevant tests;
  • Alcohol or drug abuse/dependence;
  • Pregnancy;
  • Those who have participated or are participating in other clinical studies 3 months ago;
  • Failure or refusal to sign the form.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    intervention group

    On the basis of maintaining regular medication, the intervention group received continuous Hi-tACS stimulation. The intervention was administered twice daily, in the morning and afternoon, from Monday to Friday for 2 weeks, with each session lasting 40 minutes, totaling 20 sessions.

    Device: High-intensity transcranial alternating current stimulation (Hi-tACS)

  • Sham comparator
    control group

    On the basis of maintaining regular medication, the control group received sham Hi-tACS stimulation, with each stimulation session lasting only 40 seconds. The intervention was administered twice daily, in the morning and afternoon, from Monday to Friday for 2 weeks, with each session lasting 40 minutes, totaling 20 sessions.

    Device: Sham High-intensity transcranial alternating current stimulation (Sham-Hi-tACS)

Interventions

  • DeviceHigh-intensity transcranial alternating current stimulation (Hi-tACS)

    The equipment used is the transcranial microcurrent stimulator (Nexalin ADI), operated by trained therapists following standardized instructions. Three Nexalin conductive electrodes are placed on the patient's head. A 4.45×9.53 cm electrode is placed on the forehead, corresponding to the Fpz region of the 10/20 international standard electrode placement system. Two 3.18×3.81 cm electrodes are placed on the bilateral dorsolateral prefrontal cortex, corresponding to the F3 and F4 regions of the international standard electrode placement system. The stimulation frequency is 77.5 Hz, and the current intensity is 15 mA.

  • DeviceSham High-intensity transcranial alternating current stimulation (Sham-Hi-tACS)

    A sham device looks exactly the same as Nexalin ADI is used.

06

What researchers measure

Primary outcomes

  1. Change in negative symptoms of schizophrenia

    The primary efficacy evaluation measure is the Positive and Negative Syndrome Scale (PANSS), with statistical parameters including the PANSS total score and the negative subscale score. These scores reflect the severity of schizophrenia symptoms, with higher total or subscale scores indicate more severe symptoms. A decrease in scores after the intervention indicates symptom reduction and effective intervention.

    Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)

Secondary outcomes

  1. Change in sleep quality of clinical symptom

    The sleep quality assessment measure is Pittsburgh Sleep Quality Index (PSQI). The PSQI is a widely used self-report questionnaire designed to assess sleep quality over a one-month period. The PSQI consists of 19 items, which are grouped into seven components. Each component is scored on a scale from 0 to 3, with higher scores indicating worse sleep quality. The total score ranges from 0 to 21, and a higher total score suggests poorer overall sleep quality. A decrease in the total score after the intervention suggests an improvement in sleep quality.

    Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)

  2. Change in depression of clinical symptom

    The depression assessment measure is Hamilton Depression Rating Scale (HAMD). The HAMD is a widely used tool for assessing the severity of depression in individuals. The HAMD consists of 17 items. Each item is rated on a scale ranging from 0 to 4 or 0 to 2, with higher scores indicating more severe symptoms. A decrease in the total score after the intervention suggests an improvement in depression.

    Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)

  3. Change in anxiety of clinical symptom

    The anxiety assessment measure is Hamilton Anxiety Scale (HAMA). The HAMA is a 14-item scale designed to assess the severity of anxiety symptoms in individuals. The total score ranges from 0 to 56, with higher scores indicating greater anxiety severity. A decrease in the total score after the intervention suggests an improvement in anxiety.

    Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)

  4. Change in theory of mind of social cognition

    The theory of mind assessment measure is faux pas recognition (FPT). The FPT examines the patient's recognition of the faux pas situation of the speaker. Higher total scores on the FTP indicate a better ability to recognize and understand faux pas, as well as stronger empathetic skills. An increase in the total score after the intervention suggests an improvement in theory of mind and social cognition.

    Time frame: change from baseline (W0) to 3 months after intervention (M3)

  5. Change in emotion perception of social cognition

    The emotion perception assessment measure is Face Emotion Identification Task (FEIT). The FEIT assesses the ability to perceive emotions. The score ranges from 0 to 30, with higher scores indicating better emotion perception. An increase in the total score after the intervention suggests an improvement in emotion perception.

    Time frame: change from baseline (W0) to 3 months after intervention (M3)

  6. Change in coping styles of social cognition

    The coping styles assessment measure is Simplified Coping Style Questionnaire (SCSQ). The SCSQ assesses the coping styles of individuals when facing setbacks. The overall coping style score is typically calculated as the difference between the positive coping score and the negative coping score. A higher overall score suggests a more proactive and positive coping style. An increase in the total score after the intervention suggests an improvement in positive coping style.

    Time frame: change from baseline (W0) to 3 months after intervention (M3)

  7. Change in attributional styles of social cognition

    The attributional styles assessment measure is Attributional Style Questionnaire (ASQ). The ASQ assesses attributional styles. Each cause of 12 events was rated according to locus of control (internal vs. external), stability, and globality, with higher scores indicating greater attractiveness on each dimension and a score of 4 indicating a neutral response. An increase in internal, stable, and global dimensions for positive events and a decrease in these dimensions for negative events after the intervention suggests an improvement in attributional styles.

    Time frame: change from baseline (W0) to 3 months after intervention (M3)

  8. Change in neuropsychological status of cognitive function

    The neuropsychological status of cognitive function assessment measure is the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The RBANS is widely used in clinical settings to detect cognitive impairments and track cognitive changes over time. It consists of 12 subtests that assess five primary cognitive domains: immediate memory, visuospatial/constructional skills, attention, language and delayed memory. The total RBANS score is derived by summing the five index scores and then converting this sum to a total scale score using the provided normative tables. The total scale score ranges from 40 to 160, with higher scores indicating better cognitive function. An increase in the total score after the intervention suggests an improvement in neuropsychological status of cognitive function.

    Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)

  9. Change in EEG data of cognitive function

    The electroencephalogram (EEG) data of cognitive function is P300. The P300 has been widely used in research and clinical settings to assess cognitive function. It is characterized by a positive deflection in the EEG signal that typically occurs approximately 300 milliseconds after the presentation of a target stimulus. The P300 is typically elicited using an oddball paradigm, where infrequent target stimuli are interspersed among more frequent non-target stimuli. To measure the P300, EEG data are collected using a set of electrodes placed on the scalp according to the international 10-20 system. The data are then pre-processed to remove artifacts and segmented into epochs around the stimulus onset. The average ERP is calculated for target and non-target stimuli separately, and the P300 is identified within the 250-500 ms time window.

    Time frame: change between baseline (W0), the end of intervention at 2 weeks (W2) and 3 months after intervention (M3)

  10. Change in social function

    The social function assessment measure is the Personal and Social Performance scale (PSP). The PSP is a widely used observer-rated scale for assessing patients' social functioning. The scale primarily assesses four areas of functioning in patients: useful activities in society, personal and social relationships, self-care and disruptive and aggressive behaviors. After scoring each of the four areas separately, a total score is determined according to the scoring standards. The total score ranges from 0 to 100 points and is divided into 10 levels, with higher scores reflecting better social function and interpersonal relationships. An increase in post-intervention scores indicates an improvement in social function.

    Time frame: change from baseline (W0) to 3 months after intervention (M3)

  11. Change in quality of life

    The quality of life assessment measure is the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The SF-36 scale is used to assess patients' health-related quality of life. It comprises 8 subscales with a total of 36 items, covering both physical and mental health aspects. The raw scores of each subscale are converted into standard scores ranging from 0 to 100, with higher scores indicating better quality of life in that particular domain. An increase in post-intervention scores suggests an improvement in quality of life.

    Time frame: change from baseline (W0) to 3 months after intervention (M3)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Nov 2025, 17 months after the start.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 17 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Mar 21, 2025
StartActual
Jun 27, 2024
Primary completionEst.
Nov 30, 2025
CompletionEst.
Nov 30, 2026
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06888726
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Jun 27, 2024
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jun 4, 2025

Study contacts

Qing Fan, Doctor
Contact
fanqing_98@vip.sina.com
18017311322
Qing Fan
principal investigator · Shanghai Mental Health Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion